Go Pro
NASDAQ:GDRX

GoodRx (GDRX) Stock Price, News & Analysis

GoodRx logo
$3.28 +0.01 (+0.31%)
Closing price 04:00 PM Eastern
Extended Trading
$3.28 +0.01 (+0.15%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About GoodRx Stock (NASDAQ:GDRX)

Advanced

Key Stats

Today's Range
$3.20
▼
$3.31
50-Day Range
$3.05
▼
$3.80
52-Week Range
$1.77
▼
$5.81
Volume
860,463 shs
Average Volume
808,954 shs
Market Capitalization
$1.12 billion
P/E Ratio
82.02
Dividend Yield
N/A
Price Target
$4.23
Consensus Rating
Hold

Company Overview

GoodRx Holdings, Inc. operates a healthcare technology platform that helps consumers find prescription medications at lower prices. Through its website and mobile applications, GoodRx allows users to compare prescription prices at participating pharmacies, access discount coupons and identify potential savings on commonly prescribed medications. The company’s services are primarily focused on the United States.

GoodRx also offers GoodRx Gold, a membership program that provides additional discounts on eligible prescriptions, as well as telehealth services that connect consumers with healthcare providers for certain medical consultations and prescriptions. Its platform may also provide medication information, price comparisons and tools intended to support healthcare decision-making.

In addition to its consumer offerings, GoodRx works with healthcare providers and pharmaceutical manufacturers through services designed to improve prescription access, affordability and patient engagement. The company was founded in 2011 by Trevor Bezdek, Doug Hirsch and Scott Marlette and became a publicly traded company on the Nasdaq under the symbol GDRX in 2020.

AI Generated. May Contain Errors.

GoodRx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
83rd Percentile Overall Score

GDRX MarketRank™: 

GoodRx scored higher than 83% of companies evaluated by MarketBeat, and ranked 132nd out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    GoodRx has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on no strong buy ratings, 4 buy ratings, 6 hold ratings, and 3 sell ratings.

  • Upside Potential

    GoodRx has a consensus price target of $4.23, representing about 28.9% upside from its current price of $3.28.

  • Amount of Analyst Coverage

    GoodRx has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about GoodRx's stock forecast and price target.
  • Earnings Growth

    Earnings for GoodRx are expected to grow by 25.00% in the coming year, from $0.16 to $0.20 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GoodRx is 21.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.90.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GoodRx is 21.80, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.61.

  • Price to Earnings Growth Ratio

    GoodRx has a PEG Ratio of 1.63. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    GoodRx has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about GoodRx's valuation and earnings.
  • Percentage of Shares Shorted

    1.47% of the float of GoodRx has been sold short.
  • Short Interest Ratio / Days to Cover

    GoodRx has a short interest ratio ("days to cover") of 4.44.
  • Change versus previous month

    Short interest in GoodRx has recently increased by 8.58%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    GoodRx does not currently pay a dividend.

  • Dividend Growth

    GoodRx does not have a long track record of dividend growth.

  • News Sentiment

    GoodRx has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for GoodRx this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for GDRX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GoodRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,673,207.00 in company stock.

  • Percentage Held by Insiders

    5.87% of the stock of GoodRx is held by insiders.

  • Percentage Held by Institutions

    63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about GoodRx's insider trading history.
Receive GDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GDRX Stock News Headlines

First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
GoodRx (GDRX) Stock Looks Overvalued On Its Earnings Outlook
See More Headlines

GDRX Stock Analysis - Frequently Asked Questions

GoodRx's stock was trading at $2.71 at the start of the year. Since then, GDRX shares have increased by 21.0% and is now trading at $3.28.

GoodRx Holdings, Inc. (NASDAQ:GDRX) posted its quarterly earnings results on Wednesday, August, 5th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.08 by $0.00. The business's revenue for the quarter was down 1.3% on a year-over-year basis.
Read the conference call transcript
.

GoodRx (GDRX) raised $900 million in an initial public offering (IPO) on Wednesday, September 23rd 2020. The company issued 34,615,384 shares at a price of $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays acted as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers.

Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that GoodRx investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
8/05/2026
Today
10/02/2026
Next Earnings (Estimated)
11/03/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Technology
Sub-Industry
Healthcare Technology
Current Symbol
NASDAQ:GDRX
CIK
1809519
Fax
N/A
Employees
697
Year Founded
2011

Price Target and Rating

High Price Target
$5.00
Low Price Target
$2.75
Potential Upside/Downside
+28.9%
Consensus Rating
Hold
Rating Score (0-4)
2.08
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.04
Trailing P/E Ratio
82.02
Forward P/E Ratio
20.50
P/E Growth
1.63
Net Income
$30.44 million
Net Margins
2.07%
Pretax Margin
5.27%
Return on Equity
7.22%
Return on Assets
2.53%

Debt

Debt-to-Equity Ratio
0.74
Current Ratio
1.38
Quick Ratio
1.38

Sales & Book Value

Annual Sales
$796.85 million
Price / Sales
1.41
Cash Flow
$0.40 per share
Price / Cash Flow
8.17
Book Value
$1.81 per share
Price / Book
1.81

Miscellaneous

Outstanding Shares
342,570,000
Free Float
322,465,000
Market Cap
$1.12 billion
Optionable
Optionable
Beta
1.69

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:GDRX) was last updated on 10/2/2026 by MarketBeat.com Staff.
From Our Partners